Endo Diabetes Intake - Adult

Subjective:
Chief Complaint:
Follow-up diabetes management

History of Present Illness:
Mr. Carter is a male patient presenting for follow-up of diabetes management. He reports feeling generally well since the last visit, with occasional mild fatigue. He denies new symptoms such as dizziness, vision changes, or increased urinary frequency. Mr. Carter notes intermittent numbness in his toes but denies any episodes of hypoglycemia, including symptoms such as shakiness, diaphoresis, or lightheadedness. He monitors his blood glucose at home approximately three times per week, with typical morning readings between 7 and 8 millimoles per liter. He remains adherent to his prescribed regimen of metformin and gliclazide, taken every morning and evening, and reports no adverse effects. Dietary management is maintained with increased vegetable intake, and he engages in regular physical activity, walking most days. He denies any recent falls or significant unsteadiness. There have been no new complications aside from the reported intermittent toe numbness. The most recent glycated hemoglobin was 7.2 percent. Family history of diabetes is not specified. Mr. Carter also denies other endocrinological symptoms such as polydipsia, polyphagia, or unexplained weight loss.

Past Medical History:
Type 2 diabetes mellitus without complications (E11.9).

Family History:
No family history of diabetes, thyroid conditions, or cardiovascular diseases provided.

Social History:
Mr. Carter reports increased vegetable intake as part of his diet. He engages in regular physical activity, specifically walking most days. No information provided regarding occupation, smoking status, alcohol use, drug use, or living situation.

The Review of Systems:
Constitutional – no fever, chills, weight loss, weight gain, night sweats, fatigue, or weakness. Eyes – no double vision, no blurry vision, wears glasses, no dry eyes. Integumentary – no rashes, dry skin, or eczema. Cardiovascular – no chest pain, heart palpitations, dizziness. Respiratory – no shortness of breath, no cough, no wheezing. Gastrointestinal – no nausea, vomiting, diarrhea, or constipation. Genito Urinary – no dysuria, hematuria, frequency, urgency. Musculoskeletal – no joint tenderness, redness or swelling. Neurological – no headaches or weakness, no sensory changes, no numbness or tingling, no history of seizures. Psychology – no changes in mood, no anxiety, no sleep disturbances. No dizziness, no vision changes, no tingling in feet, no increased trips to the bathroom, no episodes of low blood sugar, no feeling shaky, no feeling sweaty, no feeling lightheaded, no recent falls, no feeling unsteady.

Past Surgical History:
No surgical history provided.

Current Medications:
Metformin, taken every morning and evening. Gliclazide, taken every morning and evening. No problems with medications.

Allergies:
No allergies reported.

Objective:
Vital Signs:
No vital signs documented.

Test Results:
Most recent glycated hemoglobin (HbA1c) was 7.2 percent. Kidney function and cholesterol levels were stable.

Assessment:
Differential Diagnosis:
Type 2 diabetes mellitus without complications (E11.9). Polyneuropathy, unspecified (G62.9).

Problem:
Type 2 diabetes mellitus without complications (E11.9) with intermittent numbness in toes.

Clinical Impression:
Mr. Carter is a male with type 2 diabetes mellitus who presents for follow-up. He reports intermittent numbness in his toes but otherwise feels well. Glycemic control is reasonable with a recent HbA1c of 7.2 percent. No new complications identified.

Plan:
- Type 2 diabetes mellitus without complications (E11.9): Glycemic control remains stable with recent glycated hemoglobin measured at 7.2 percent. The patient reports adherence to metformin and gliclazide, with no adverse effects. Home blood glucose monitoring demonstrates fasting values between 7 and 8 millimoles per liter. The patient denies symptoms of hypoglycemia, including shakiness, diaphoresis, or lightheadedness. Mild intermittent numbness in the toes is reported, without associated falls or significant unsteadiness. No new visual disturbances or increased urinary frequency are noted. 
Plan:
• Continue current regimen of metformin and gliclazide at established dosages, taken every morning and evening.
• Maintain home blood glucose monitoring at least three times per week, with continued documentation of results.
• Reinforce dietary management with increased vegetable intake and encourage ongoing regular physical activity, such as daily walking as tolerated.
• Arrange for a comprehensive foot examination at the next visit to assess for peripheral neuropathy and reinforce the importance of wearing supportive footwear at home.
• Order repeat laboratory studies, including glycated hemoglobin, renal function, and lipid profile, in three months to monitor ongoing metabolic control and end-organ status.
• Schedule follow-up appointment in approximately three months to review laboratory results, assess glycemic control, and perform foot evaluation.
• Advise the patient to report any new symptoms, including hypoglycemic episodes, worsening neuropathy, or changes in vision, prior to the next scheduled visit.
• Provide education regarding the importance of medication adherence, regular monitoring, and foot care to reduce the risk of diabetes-related complications.


- Polyneuropathy, unspecified (G62.9): The patient reports intermittent numbness in the toes, without associated pain, ulceration, or functional impairment. No recent falls or significant unsteadiness are reported.
Plan:
• Schedule a focused foot examination at the next visit to assess for sensory deficits, skin integrity, and risk of ulceration.
• Reinforce the use of supportive footwear at home to minimize trauma and reduce risk of foot injury.
• Monitor for progression of neuropathic symptoms and educate the patient on daily foot inspection and prompt reporting of any new changes.


Follow Up:
Follow-up appointment scheduled in approximately three months. No questions or concerns.

Clinic Name: Regional Medical Center

Assessment and Plan:
- Type 2 diabetes mellitus without complications (E11.9): Glycemic control remains stable with recent glycated hemoglobin measured at 7.2 percent. The patient reports adherence to metformin and gliclazide, with no adverse effects. Home blood glucose monitoring demonstrates fasting values between 7 and 8 millimoles per liter. The patient denies symptoms of hypoglycemia, including shakiness, diaphoresis, or lightheadedness. Mild intermittent numbness in the toes is reported, without associated falls or significant unsteadiness. No new visual disturbances or increased urinary frequency are noted. 
Plan:
• Continue current regimen of metformin and gliclazide at established dosages, taken every morning and evening.
• Maintain home blood glucose monitoring at least three times per week, with continued documentation of results.
• Reinforce dietary management with increased vegetable intake and encourage ongoing regular physical activity, such as daily walking as tolerated.
• Arrange for a comprehensive foot examination at the next visit to assess for peripheral neuropathy and reinforce the importance of wearing supportive footwear at home.
• Order repeat laboratory studies, including glycated hemoglobin, renal function, and lipid profile, in three months to monitor ongoing metabolic control and end-organ status.
• Schedule follow-up appointment in approximately three months to review laboratory results, assess glycemic control, and perform foot evaluation.
• Advise the patient to report any new symptoms, including hypoglycemic episodes, worsening neuropathy, or changes in vision, prior to the next scheduled visit.
• Provide education regarding the importance of medication adherence, regular monitoring, and foot care to reduce the risk of diabetes-related complications.


- Polyneuropathy, unspecified (G62.9): The patient reports intermittent numbness in the toes, without associated pain, ulceration, or functional impairment. No recent falls or significant unsteadiness are reported.
Plan:
• Schedule a focused foot examination at the next visit to assess for sensory deficits, skin integrity, and risk of ulceration.
• Reinforce the use of supportive footwear at home to minimize trauma and reduce risk of foot injury.
• Monitor for progression of neuropathic symptoms and educate the patient on daily foot inspection and prompt reporting of any new changes.